Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | MEN1 | O00255 | 13/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 12/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.49 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.49 |
| ▸ | NSD2 | O96028 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1604201 | 0.91 | HTT (0.75) | HTTSMN1; SMN2MEN1KMT2ARAB9A | |
| SCHEMBL1605139 | 0.87 | HTT (1.00) | HTTSMN1; SMN2MEN1KMT2ARAB9A | |
| SCHEMBL12533525 | 0.84 | MEN1 (0.66) | HTTSMN1; SMN2MEN1KMT2AHTR2B | |
| SCHEMBL1604148 | 0.84 | HTR2B (0.70) | HTTSMN1; SMN2MEN1KMT2ARAB9A | |
| SCHEMBL1604038 | 0.78 | HTT (0.52) | HTTSMN1; SMN2MEN1KMT2ARAB9A | |
| SCHEMBL1604250 | 0.78 | MEN1 (0.67) | HTTSMN1; SMN2MEN1KMT2ARAB9A | |
| SCHEMBL1604266 | 0.78 | MEN1 (0.77) | HTTSMN1; SMN2MEN1KMT2ARAB9A | |
| SCHEMBL1921558 | 0.76 | HTT (0.50) | HTTSMN1; SMN2MEN1KMT2ARAB9A | |
| SCHEMBL1605136 | 0.76 | MEN1 (0.57) | HTTSMN1; SMN2MEN1KMT2ARAB9A | |
| SCHEMBL11890534 | 0.74 | EHMT2 (0.46) | HTTSMN1; SMN2MEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110082157-A1 | Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds | TROVIS PHARMACEUTICALS, LLC | 2011-04-07 | — | — | US | disclosed |
| US-20110082157-A1 | Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds | TROVIS PHARMACEUTICALS, LLC | 2011-04-07 | — | — | US | disclosed |
| US-20100113485-A1 | Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds | TROVIS PHARMACEUTICALS, LLC | 2010-05-06 | — | — | US | disclosed |
| US-20100113485-A1 | Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds | TROVIS PHARMACEUTICALS, LLC | 2010-05-06 | — | — | US | disclosed |
| US-7612078-B2 | Piperidinylamino-thieno[2,3-D] pyrimidine compounds | EPIX DELAWARE, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612078-B2 | Piperidinylamino-thieno[2,3-D] pyrimidine compounds | EPIX DELAWARE, INC. (US) | 2009-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113485-A1 | Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds | HTR2B, HTR3B, HTR1B | HTT 2061/4885SMN1; SMN2 4727/4885MEN1 4118/4885 |
| US-20110082157-A1 | Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds | HTR5A, HTR3A, HTR1A | HTT 3083/4885SMN1; SMN2 1383/4885MEN1 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.